Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Recursion Pharmaceuticals Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.28, while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.53B). The key difference: KraneShares Hang Seng TECH Index ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| KTEC | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $19.51 | $6.79 |
52-Week Low | $12.00 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.
Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
